Viveve Medical (NASDAQ:VIVE) – Equities research analysts at Zacks Investment Research increased their Q2 2018 earnings per share (EPS) estimates for shares of Viveve Medical in a research note issued to investors on Thursday, May 17th. Zacks Investment Research analyst B. Marckx now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.39). Zacks Investment Research also issued estimates for Viveve Medical’s Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.37) EPS, FY2018 earnings at ($1.60) EPS, FY2019 earnings at ($1.17) EPS and FY2020 earnings at ($0.96) EPS.
Several other brokerages have also issued reports on VIVE. ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Mizuho reissued a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a report on Thursday, February 1st. Maxim Group reissued a “buy” rating and issued a $11.00 price target on shares of Viveve Medical in a report on Friday, March 16th. Stifel Nicolaus began coverage on shares of Viveve Medical in a report on Tuesday, April 17th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Craig Hallum lowered shares of Viveve Medical from a “buy” rating to a “hold” rating in a report on Friday, May 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. Viveve Medical presently has a consensus rating of “Buy” and a consensus target price of $9.33.
Shares of Viveve Medical opened at $1.85 on Monday, Marketbeat reports. Viveve Medical has a 12-month low of $1.60 and a 12-month high of $8.75. The firm has a market capitalization of $59.72 million, a PE ratio of -0.88 and a beta of -0.44. The company has a debt-to-equity ratio of 1.55, a current ratio of 6.47 and a quick ratio of 6.00.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Viveve Medical had a negative net margin of 269.24% and a negative return on equity of 437.98%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.68 million.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. RTW Investments LP boosted its stake in Viveve Medical by 13.6% in the 4th quarter. RTW Investments LP now owns 1,672,998 shares of the company’s stock worth $8,315,000 after purchasing an additional 199,970 shares during the period. venBio Select Advisor LLC boosted its stake in Viveve Medical by 48.4% in the 1st quarter. venBio Select Advisor LLC now owns 1,533,276 shares of the company’s stock worth $5,612,000 after purchasing an additional 500,000 shares during the period. BlackRock Inc. boosted its stake in Viveve Medical by 8.1% in the 1st quarter. BlackRock Inc. now owns 780,591 shares of the company’s stock worth $2,857,000 after purchasing an additional 58,256 shares during the period. Wexford Capital LP boosted its stake in Viveve Medical by 152.5% in the 1st quarter. Wexford Capital LP now owns 698,200 shares of the company’s stock worth $2,555,000 after purchasing an additional 421,700 shares during the period. Finally, Acuta Capital Partners LLC boosted its stake in Viveve Medical by 58.1% in the 1st quarter. Acuta Capital Partners LLC now owns 685,215 shares of the company’s stock worth $2,508,000 after purchasing an additional 251,796 shares during the period. 64.83% of the stock is owned by hedge funds and other institutional investors.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.